understanding resistance to combined braf and mek inhibiton in melanoma and the significance of cdk4
Published 7 years ago • 343 plays • Length 4:07Download video MP4
Download video MP3
Similar videos
-
2:10
combined treatment with braf and mek inhibitors in metastatic melanomas with braf mutations
-
1:30
blocking c-met and braf pathways in melanoma to overcome resistance in mouse models
-
2:23
the future of tyrosine kinase inhibitors for melanoma and open questions
-
2:58
role of braf mutation in the treatment for melanoma
-
2:01
what's next in melanoma research on drug resistance?
-
6:22
braf and mek in melanoma
-
9:24
anti-pd1 monotherapy or combination with ipi after braf/mek inhibitors in braf-mutant melanoma
-
2:02
mek inhibitors for melanoma: new combination approved
-
2:10
using biomarkers to predict response to combination therapies in braf-mutant melanoma
-
0:52
dr. kudchadkar on combining braf and mek inhibitors to treat melanoma
-
8:47
braf/mek inhibitors in metastatic melanoma
-
2:29
braf mutated melanoma: targeted or immunotherapy?
-
9:49
melanoma: nuances of braf/mek combinations in the front line
-
6:05
duration of dual braf-mek inhibition
-
4:18
braf/mek inhibition as adjuvant treatment in melanoma
-
8:40
melanoma: braf/mek targeted therapy
-
1:33
dr. paul chapman on braf and mek inhibitor combination for advanced melanoma
-
3:19
encorafenib in a combination regimen for braf melanoma
-
6:10
inhibition of mek to treat cancer: focus on melanoma